Sign in to view content

Novel Vascular Endothelial Growth-Factor A (VEGF-A) and Angiopoietin-2 (Ang-2) Bispecific Protein, RO-634, in Comparison to Aflibercept

Mark R. Barakat, MD

Video
Published 2022

Related

Personalized Treatment Interval Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema
John W. Kitchens, MD
Annual Meeting Talks
2022
High-Dose Anti-VEGF: Cross-Trial Analysis of Different Doses and Antagonists for the Treatment of Diabetic Macular Edema
Quan Dong Nguyen, MD, MSc, FARVO, FASRS
On Demand Cases, Courses, and Papers
2019
Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibiz
Susan B. Bressler, MD, FASRS
Updates from the Field
2017

Category: Pharmacology

See more